A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of Asn002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors

Trial Profile

A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of Asn002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs ASN 002 (Primary)
  • Indications B cell lymphoma; Diffuse lymphoma; Follicular lymphoma; Large cell carcinoma; Lymphoma; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Asana BioSciences
  • Most Recent Events

    • 25 Jul 2017 Planned number of patients changed from 80 to 148.
    • 25 Jul 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
    • 25 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top